TIDMOBD
RNS Number : 6823Y
Oxford BioDynamics PLC
14 May 2021
14 May 2021
Oxford BioDynamics Plc
( "OBD" or the "Company" and, together with its subsidiaries,
the "Group")
PDMR Dealing / Grant of Share Options
Oxford BioDynamics Plc (AIM: OBD, the Company), a biotechnology
company developing precision medicine tests for personalized
healthcare based on the EpiSwitch(R) 3D genomics platform,
announces that it has today granted a total of 1,632,798 options
over its ordinary shares of 1 pence each ("Ordinary Shares"), to
certain Group employees, including 462,798 options to Chief
Executive Officer, Dr Jon Burrows, 480,000 options to Chief
Financial Officer, Paul Stockdale and 150,000 options to Chief
Operating Officer, Thomas Guiel, who is a person discharging
managerial responsibility. The options were granted under the
Company's 2016 Employee Share Option Plan with an exercise price of
GBP1 per share.
One-third of the options granted will vest and become
exercisable on the first anniversary of the grant date; one-third
on the second anniversary and one-third on the third anniversary.
Vested options will remain exercisable up to and including the
tenth anniversary of the date of grant.
Following this grant, Dr Jon Burrows, Paul Stockdale and Thomas
Guiel hold options over Ordinary Shares and are interested in
Ordinary Shares as follows:
Total number Ordinary Shares held
of options over
Ordinary Shares
Number % of current
issued share
capital
------- --------------
Jon Burrows 1,388,396 Nil -
----------------- ------- --------------
Paul Stockdale 600,000 15,000 0.02
----------------- ------- --------------
Thomas Guiel 150,000 Nil -
----------------- ------- --------------
The information set out below is provided in accordance with the
requirements of Article 19(3) of the EU Market Abuse Regulation No
596/2014.
1 Details of the person discharging managerial responsibilities/person
closely associated
a) Name Jon Burrows
-------------------------- ---------------------------------------------
2 Reason for the notification
-------------------------------------------------------------------------
a) Position/status Director/PDMR
-------------------------- ---------------------------------------------
b) Initial notification/ Initial notification
Amendment
-------------------------- ---------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------------
a) Name Oxford BioDynamics Plc
-------------------------- ---------------------------------------------
b) LEI 2138005Y1TK258O5U928
-------------------------- ---------------------------------------------
4 Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii)
each date; and (iv) each place where transactions have been
conducted
-------------------------------------------------------------------------
a) Description of the Ordinary Shares of 1 pence each
financial instrument, ISIN: GB00BD5H8572
type of instrument
Identification code
-------------------------- ---------------------------------------------
b) Nature of the transaction Grant of share options
-------------------------- ---------------------------------------------
c) Price(s) and volume(s) 462,798 ordinary shares at an exercise price
of 100 pence per share
-------------------------- ---------------------------------------------
d) Aggregated information N/A
- Aggregated volume
- Price
-------------------------- ---------------------------------------------
e) Date of the transaction 14 May 2021
-------------------------- ---------------------------------------------
f) Place of the transaction Outside a trading venue
-------------------------- ---------------------------------------------
1 Details of the person discharging managerial responsibilities/person
closely associated
a) Name Paul Stockdale
-------------------------- ---------------------------------------------
2 Reason for the notification
-------------------------------------------------------------------------
a) Position/status Director/PDMR
-------------------------- ---------------------------------------------
b) Initial notification/ Initial notification
Amendment
-------------------------- ---------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------------
a) Name Oxford BioDynamics Plc
-------------------------- ---------------------------------------------
b) LEI 2138005Y1TK258O5U928
-------------------------- ---------------------------------------------
4 Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii)
each date; and (iv) each place where transactions have been
conducted
-------------------------------------------------------------------------
a) Description of the Ordinary Shares of 1 pence each
financial instrument, ISIN: GB00BD5H8572
type of instrument
Identification code
-------------------------- ---------------------------------------------
b) Nature of the transaction Grant of share options
-------------------------- ---------------------------------------------
c) Price(s) and volume(s) 480,000 ordinary shares at an exercise price
of 100 pence per share
-------------------------- ---------------------------------------------
d) Aggregated information N/A
- Aggregated volume
- Price
-------------------------- ---------------------------------------------
e) Date of the transaction 14 May 2021
-------------------------- ---------------------------------------------
f) Place of the transaction Outside a trading venue
-------------------------- ---------------------------------------------
1 Details of the person discharging managerial responsibilities/person
closely associated
a) Name Thomas Guiel
-------------------------- ---------------------------------------------
2 Reason for the notification
-------------------------------------------------------------------------
a) Position/status PDMR
-------------------------- ---------------------------------------------
b) Initial notification/ Initial notification
Amendment
-------------------------- ---------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------------
a) Name Oxford BioDynamics Plc
-------------------------- ---------------------------------------------
b) LEI 2138005Y1TK258O5U928
-------------------------- ---------------------------------------------
4 Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii)
each date; and (iv) each place where transactions have been
conducted
-------------------------------------------------------------------------
a) Description of the Ordinary Shares of 1 pence each
financial instrument, ISIN: GB00BD5H8572
type of instrument
Identification code
-------------------------- ---------------------------------------------
b) Nature of the transaction Grant of share options
-------------------------- ---------------------------------------------
c) Price(s) and volume(s) 150,000 ordinary shares at an exercise price
of 100 pence per share
-------------------------- ---------------------------------------------
d) Aggregated information N/A
- Aggregated volume
- Price
-------------------------- ---------------------------------------------
e) Date of the transaction 14 May 2021
-------------------------- ---------------------------------------------
f) Place of the transaction Outside a trading venue
-------------------------- ---------------------------------------------
-Ends-
For further details please contact:
Oxford BioDynamics Plc Tel: +44 (0)1865
Jon Burrows, CEO 518910
Paul Stockdale, CFO
Shore Capital - Nominated Adviser and Tel: +44 (0)20
Broker 7408 4090
Advisory: Edward Mansfield / John More
Broking: Fiona Conroy
Instinctif Partners Tel: +44 (0)20
Melanie Toyne-Sewell / Agnes Stephens 7457 2020
/ OxfordBioDynamics@instinctif.com
Katie Duffell / Nathan Billis
Notes for Editors
About Oxford BioDynamics Plc
Oxford BioDynamics Plc (AIM: OBD) is a global biotechnology
company, advancing personalized healthcare by developing and
commercializing precision medicine tests for life-changing
diseases.
The Company has developed a proprietary 3D genomic biomarker
platform, EpiSwitch(R), which can build molecular diagnostic
classifiers for prediction of response to therapy, patient
prognosis, disease diagnosis and subtyping, and residual disease
monitoring in a wide range of indications.
In March 2021, the Company launched its first commercial
prognostic test, EpiSwitch (R) CST (Covid Severity Test) and the
first commercially available microarray kit for high-resolution 3D
genome profiling and biomarker discovery, EpiSwitch(R) Explorer
Array Kit . Its next product will be a predictive immune response
profile for immuno-oncology (IO) checkpoint inhibitor treatments,
to be launched later in 2021.
Oxford BioDynamics has participated in more than 40 partnerships
with big pharma and leading institutions including Pfizer, EMD
Serono, Genentech, Roche, Biogen, Mayo Clinic, Massachusetts
General Hospital and Mitsubishi Tanabe Pharma.
The Company has created a valuable technology portfolio,
including biomarker arrays, molecular diagnostic tests,
bioinformatic tools for 3D genomics and an expertly curated 3D
genome knowledgebase comprising hundreds of millions of data points
from over 10,000 samples in more than 30 human diseases.
OBD is headquartered in Oxford, UK and is listed on AIM of the
London Stock Exchange. It also has a commercial team in the US and
a reference laboratory in Penang, Malaysia
For more information, please visit the Company's website ,
www.oxfordbiodynamics.com , or follow on Twitter or LinkedIn .
About EpiSwitch(R)
The 3D configuration of the genome plays a crucial role in gene
regulation. By mapping this architecture and identifying abnormal
configurations, EpiSwitch(R) can be used to diagnose patients or
determine how individuals might respond to a disease or
treatment.
Built on over 10 years of research, EpiSwitch(R) is Oxford
Biodynamics' award-winning, proprietary platform that enables
screening, evaluation, validation and monitoring of 3D genomic
biomarkers. The technology is fully developed, based on testing of
over 10,000 samples in 30 disease areas, and reduced to
practice.
In addition to stratifying patients with respect to anticipated
clinical outcome, EpiSwitch(R) data offer insights into systems
biology and the physiological manifestation of disease that are
beyond the scope of other molecular modalities. The technology has
performed well in academic medical research settings and has been
validated through its integration in biomarker discovery and
clinical development with big pharma.
Oxford BioDynamics is leveraging its technology to develop a
pipeline of tests in a wide range of indications, such as
immuno-oncology, neurodegenerative and autoimmune diseases, to
follow its commercial EpiSwitch (R) CST (Covid Severity Test).
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHGIGDUIUBDGBS
(END) Dow Jones Newswires
May 14, 2021 05:17 ET (09:17 GMT)
Oxford Biodynamics (LSE:OBD)
Historical Stock Chart
From Apr 2024 to May 2024
Oxford Biodynamics (LSE:OBD)
Historical Stock Chart
From May 2023 to May 2024